GSK Gears Up for Q4 Earnings: Will It Surpass Estimates?

We expect GSK plc. (GSK) to beat expectations when it reports fourth-quarter and full-year 2023 results on Jan 31. In the last reported quarter, the company delivered an earnings surprise of 15.60%.Factors to NoteGSK reports financial figures under three segments — Specialty Medicines, Vaccines and General Medicines.In the fourth quarter, higher sales of newer products like Arexvy, Cabenuva, Dovato, Trelegy Ellipta and Shingrix are likely to have offset the decline in sales of older HIV drugs and respirator ...